Trial Profile

A proof of efficacy, phase 2 clinical study of THRV-1268.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs THRV 1268 (Primary)
Indications Heart failure; Paroxysmal atrial fibrillation
Focus Proof of concept; Therapeutic Use
Acronyms Aspire study

Most Recent Events

31 Oct 2025 New trial record
08 Sep 2025 According to Thryv Therapeutics media release, company plans to initiate the Phase 2 proof of efficacy Aspire study in heart failure and obesity-associated paroxysmal atrial fibrillation in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com